# OnCo record instil-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/instil-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "instil-bio" ;
  schema:name "Instil Bio"@en ;
  schema:alternateName "Axion Bio"@en ;
  schema:description "Instil Bio is a listed biotechnology company that previously developed immune cell therapies and then a two-target antibody for solid tumours. It stopped that antibody programme in January 2026 and now seeks new medicines to acquire or license."@en ;
  schema:url <https://onco.cc/companies/instil-bio/>, <https://instilbio.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://instilbio.com/>, <https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm>, <https://clinicaltrials.gov/study/NCT07159828> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/til-therapy/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/> .